A message from Goodway Technologies Corporation

Delivering Massive Efficiency (and Bottom-Line) Gains Through Chemical Descaling

Astatine-211 targets blood-borne cancers in Seattle clinical trials

September 13, 2022, 9:30AMNuclear News

A clinical dose of At-211 is prepared at the University of Washington for use in a Fred Hutchison Cancer Center clinical trial. (Photo: UW/Don Hamlin)

Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

To continue reading, log in or create a free account!

Deep Fission to break ground this week

December 8, 2025, 6:58AMNuclear News

With about seven months left in the race to bring DOE-authorized test reactors on line by July 4, 2026, via the Reactor Pilot Program, Deep Fission has announced that it will break ground on...

Project delivers a universal waste canister for advanced reactors

December 4, 2025, 3:45PMRadwaste Solutions

Nuclear waste disposal technology company Deep Isolation Nuclear has announced the completion of a three-year project to manufacture, physically test, and validate a disposal-ready universal...

Project Pele progress: BWXT delivers fuel to INL

December 4, 2025, 12:00PMNuclear News

This week, BWX Technologies, alongside Idaho National Laboratory and the Department of Defense’s Strategic Capabilities Office, announced the arrival of a full core of TRISO fuel at INL’s...

ANS hosts webinar on uranium mill tailing facilities

December 1, 2025, 7:02AMANS News

The American Nuclear Society’s Risk-informed, Performance-based Principles and Policy Committee (RP3C) has held another presentation in its monthly Community of Practice (CoP) series. Former...

White House to consolidate data and research under AI-driven Genesis Mission

November 26, 2025, 9:49AMNuclear News

One of the executive orders issued by President Trump in November —“Launching the Genesis Mission”—focuses on a national effort to accelerate the use of AI in scientific research. The...

The DOE reorganization’s impact on nuclear

November 26, 2025, 7:00AMNuclear News

In a recent press release, the Department of Energy announced an organizational realignment aimed at “expanding American energy production, accelerating scientific and technological...

My story: Abraham Weitzberg, ANS member since 1962

November 25, 2025, 9:31AMANS NewsAbraham Weitzberg

My first exposure to nuclear engineering was in 1956–57 when I was a fourth-year chemical engineering undergraduate at MIT. The previous summer, I worked at an oil refinery in New Jersey...

Construction begins on X-energy’s Oak Ridge advanced fuel facility

November 18, 2025, 12:07PMNuclear News

Small modular reactor developer X-energy and its subsidiary TRISO-X announced yesterday the start of aboveground construction for its TX-1 advanced nuclear fuel fabrication facility in Oak...

The progress so far: An update on the Reactor Pilot Program

November 14, 2025, 12:10PMNuclear News

It has been about three months since the Department of Energy named 10 companies for its new Reactor Pilot Program, which maps out how the DOE would meet the goal announced in May by Executive...

New financing round benefits Valar

November 13, 2025, 3:00PMNuclear News

Hawthorne, Calif.–based reactor start-up Valar Atomics recently announced that it has raised $130 million in its Series A funding round, led by venture capital groups Snowpoint, Day One, and...

Astatine-211 targets blood-borne cancers in Seattle clinical trials

Related Articles